Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sefaxersen sodium by F. Hoffmann-La Roche for IgA Nephropathy (Berger's Disease): Likelihood of Approval
Sefaxersen sodium is under clinical development by F. Hoffmann-La Roche and currently in Phase III for IgA Nephropathy (Berger's Disease)....
Risk adjusted net present value: What is the current valuation of Roche's Sefaxersen sodium?
Sefaxersen sodium is an antisense oligonucleotide commercialized by Roche, with a leading Phase III program in IgA Nephropathy (Berger's Disease)....
Sefaxersen sodium by F. Hoffmann-La Roche for Geographic Atrophy: Likelihood of Approval
Sefaxersen sodium is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Geographic Atrophy. According to...